Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (6699)	7/16/1998 3:44:00 PM
From: aknahow	Respond to of 17367

What was the sum?

To: Robert S. who wrote (6699)	7/19/1998 1:15:00 PM
From: Robert K.	Respond to of 17367

According to the company in 1995 (their views may have changed)>> >>>below is from 1995 annual report>> One other consideration guided our choice of indications. We chose indications that represent large and commercially attractive markets themselves (such as trauma or intra-abdominal infections), or indications (such as meningococcemia and partial hepatectomy) that also provide proofs-of-concept for large markets. We believe that the market for Neuprex represented by the four trials now in progress is potentially in excess of a billion dollars.<end IMO (not that of the company)> My opinions belows.(not xomas) meningococcemia= a form of sepsis hem trauma has been replaced by a equally large market>Pneumonia Partial hepatectomy=might equal liver transplant or hepatitis or even perhaps cirrhosis. Abdominal might be a prelude to surgical prophylaxis Question again, how much can they charge? All disclaimers always apply. Remember, some of the above are xomas comments in 1995, cicumstances may have changed. All the rest is IMO, and value as worthless opinion.